ondansetron has been researched along with Schizophrenia in 16 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials." | 9.27 | Ondansetron - a promising adjunctive treatment for persistent schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2018) |
| "This is a two center, six-month, double-blind placebo controlled, factorial design study of ondansetron and/or simvastatin added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder." | 9.17 | Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial. ( Chaudhry, IB; Deakin, B; Drake, R; Dunn, G; Hallak, J; Hamirani, MM; Husain, MO; Husain, N; Kazmi, A; Kiran, T; Mehmood, N; Rahman, Ru; Stirling, J, 2013) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 9.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design." | 9.11 | Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. ( Adler, LE; Cawthra, EM; Donovan, KA; Harris, JG; Nagamoto, HT; Olincy, A; Waldo, MC, 2005) |
| "This randomized control trial compared adjunctive (8 mg/daily) ondansetron or placebo to commonly prescribed atypical antipsychotics for people suffering with chronic schizophrenia ( ClinicalTrials." | 5.27 | Ondansetron - a promising adjunctive treatment for persistent schizophrenia. ( Gavrilidis, E; Gurvich, C; Hudaib, AR; Kulkarni, J; Thomas, N, 2018) |
| "This is a two center, six-month, double-blind placebo controlled, factorial design study of ondansetron and/or simvastatin added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder." | 5.17 | Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial. ( Chaudhry, IB; Deakin, B; Drake, R; Dunn, G; Hallak, J; Hamirani, MM; Husain, MO; Husain, N; Kazmi, A; Kiran, T; Mehmood, N; Rahman, Ru; Stirling, J, 2013) |
| "Under double-blind, randomized conditions, 121 treatment-resistant inpatients with chronic DSM-IV-diagnosed schizophrenia received haloperidol (4-30 mg/day) combined with either placebo (N=63) or a fixed dose of 8 mg/day of ondansetron (N=58) for 12 weeks." | 5.12 | Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. ( Kang, WH; Li, Q; Ma, AQ; Wang, XY; Yao, SM; Zhang, ZJ, 2006) |
| "Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design." | 5.11 | Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. ( Adler, LE; Cawthra, EM; Donovan, KA; Harris, JG; Nagamoto, HT; Olincy, A; Waldo, MC, 2005) |
| "Twenty patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given 12 mg/day of ondansetron for 12 weeks in an open-label study." | 5.09 | Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. ( Giladi, N; Korczyn, AD; Mosheva, T; Shabtay, H; Sirota, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Juza, R | 1 |
| Vojtechova, I | 1 |
| Stefkova-Mazochova, K | 1 |
| Dehaen, W | 1 |
| Petrasek, T | 1 |
| Prchal, L | 1 |
| Kobrlova, T | 1 |
| Janousek, J | 1 |
| Vlcek, P | 1 |
| Mezeiova, E | 1 |
| Svozil, D | 1 |
| Karasova, JZ | 1 |
| Pejchal, J | 1 |
| Stark, H | 1 |
| Satala, G | 1 |
| Bojarski, AJ | 1 |
| Kubacka, M | 1 |
| Mogilski, S | 1 |
| Randakova, A | 1 |
| Musilek, K | 1 |
| Soukup, O | 1 |
| Korabecny, J | 1 |
| Yadav, S | 1 |
| Takács, A | 1 |
| Pantelis, C | 1 |
| Thomas, N | 2 |
| Kulkarni, J | 1 |
| Hudaib, AR | 1 |
| Gavrilidis, E | 1 |
| Gurvich, C | 1 |
| Zheng, W | 1 |
| Cai, DB | 1 |
| Zhang, QE | 1 |
| He, J | 1 |
| Zhong, LY | 1 |
| Sim, K | 1 |
| Ungvari, GS | 1 |
| Ning, YP | 1 |
| Xiang, YT | 1 |
| Chaudhry, IB | 1 |
| Husain, N | 1 |
| Husain, MO | 1 |
| Hallak, J | 1 |
| Drake, R | 1 |
| Kazmi, A | 1 |
| Rahman, Ru | 1 |
| Hamirani, MM | 1 |
| Kiran, T | 1 |
| Mehmood, N | 1 |
| Stirling, J | 1 |
| Dunn, G | 1 |
| Deakin, B | 1 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Hema, T | 1 |
| Maran, S | 1 |
| Subhashini, G | 1 |
| Akhondzadeh, S | 1 |
| Mohammadi, N | 1 |
| Noroozian, M | 1 |
| Karamghadiri, N | 1 |
| Ghoreishi, A | 1 |
| Jamshidi, AH | 1 |
| Forghani, S | 1 |
| Adler, LE | 1 |
| Cawthra, EM | 1 |
| Donovan, KA | 1 |
| Harris, JG | 1 |
| Nagamoto, HT | 1 |
| Olincy, A | 1 |
| Waldo, MC | 1 |
| Levkovitz, Y | 1 |
| Arnest, G | 1 |
| Mendlovic, S | 1 |
| Treves, I | 1 |
| Fennig, S | 1 |
| Zhang, ZJ | 1 |
| Kang, WH | 1 |
| Li, Q | 1 |
| Wang, XY | 1 |
| Yao, SM | 1 |
| Ma, AQ | 1 |
| Olié, JP | 1 |
| Baylé, FJ | 1 |
| Briskin, JK | 1 |
| Curtis, JL | 1 |
| Sirota, P | 2 |
| Mosheva, T | 2 |
| Shabtay, H | 1 |
| Giladi, N | 1 |
| Korczyn, AD | 2 |
| Shabtai, H | 1 |
| White, A | 1 |
| Corn, TH | 1 |
| Feetham, C | 1 |
| Faulconbridge, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia[NCT01121042] | Phase 3 | 85 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment as Usual in Patients With Schizophrenia[NCT01602029] | Phase 2 | 303 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Atypical Antipsychotics and P50 Sensory Gating[NCT00149734] | Phase 3 | 8 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
P50 Sensory Gating as measured by evoked potentials (response to stimuli, in this case, clicking sounds).The P50 potential was identified and measured using a computer algorithm. The amplitude of the P50 test wave was divided by the amplitude of the P50 conditioning wave, expressed as a percentage: the P50 ratio. Lower P50 ratios represent better outcomes. (NCT00149734)
Timeframe: Up to 3 hours
| Intervention | percentage (Mean) |
|---|---|
| Ondansetron | 41.4 |
| Placebo | 80.2 |
3 reviews available for ondansetron and Schizophrenia
| Article | Year |
|---|---|
Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Humans; Ondansetron; Schizophrenia; Treatment Outco | 2019 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
[New drug therapies].
Topics: Brain; Clozapine; Humans; Ondansetron; Psychiatric Status Rating Scales; Psychotropic Drugs; Schizop | 1996 |
7 trials available for ondansetron and Schizophrenia
| Article | Year |
|---|---|
Ondansetron - a promising adjunctive treatment for persistent schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognitive Dysfunction; Double-Blind Method; Drug Therapy, Combination; | 2018 |
Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Brazil; Checklist; Clinical Protocols; Cognition; Do | 2013 |
Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Cognition Disorders; Double-Blin | 2009 |
Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Cross-Over Studies; Double-Blind Method; Drug The | 2005 |
The effect of Ondansetron on memory in schizophrenic patients.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Memory; | 2005 |
Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Diagnostic and Statistical Manual of | 2006 |
Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; H | 2000 |
6 other studies available for ondansetron and Schizophrenia
| Article | Year |
|---|---|
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
Ondansetron augmentation for the management of obsessive-compulsive disorder in a patient with treatment-resistant schizophrenia.
Topics: Humans; Obsessive-Compulsive Disorder; Ondansetron; Schizophrenia; Selective Serotonin Reuptake Inhi | 2021 |
Adjunctive ondansetron in schizophrenia--A pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Feasibility Studies; | 2016 |
Augmentation of clozapine therapy with ondansetron.
Topics: Adult; Animals; Chronic Disease; Clozapine; Drug Synergism; Drug Therapy, Combination; Humans; Male; | 1997 |
Treating tardive dyskinesia with ondansetron.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Ondansetron; Schizophrenia; Serot | 2001 |
Ondansetron in treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Combined Modality Therapy; Humans; Imidazoles; Male; Ondansetron; Schiz | 1991 |